微波消融治疗多灶性甲状腺微小乳头状癌的远期疗效:5年随访研究
本研究回顾性纳入66例低危多灶性甲状腺微小乳头状癌患者共158个病灶,均接受超声引导下微波消融,随访至60个月时全部病灶消失,技术成功率与体积缩小率均为100%,并发症率与肿瘤进展率均为3.03%(2/66)。作者认为超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效,可能作为拒绝手术或主动监测患者的替代选择。
要点
- 随访60个月时66例患者共158个病灶全部消失,体积由43.82 mm3降至0.00 mm3。
- 技术成功率与体积缩小率均为100%,1年、2年、3年完全消失率分别为57.59%、93.67%、100%。
- 并发症率3.03%(2/66),肿瘤进展率3.03%(2/66),含1个新发甲状腺内病灶和1枚颈部淋巴结转移。
核心结论
- 超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效,可能作为拒绝手术或主动监测患者的替代选择。
研究设计与样本
- 回顾性分析66例低危多灶性甲状腺微小乳头状癌患者共158个病灶,均接受微波消融,收集消融前及治疗后1、3、6、12个月、此后每6个月直至治疗后5年的随访数据。
关键影像表现/征象
- 随访60个月时66例患者共158个病灶全部消失,病灶体积由43.82 mm3降至0.00 mm3。
- 随访期间技术成功率和体积缩小率均为100%。
- 随访中2例(3.03%)出现肿瘤进展,分别为1个新发甲状腺内病灶和1枚颈部淋巴结转移,均再次行微波消融后病灶于随访期内消失。
诊断标准与关键数值
- 1年、2年、3年完全消失率分别为57.59%、93.67%、100%。
- 并发症率为3.03%(2/66),肿瘤进展发生率为3.03%(2/66)。
临床应用与阅片要点
- 作者认为超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效,可能作为拒绝手术或主动监测患者的替代选择。
- 原文指出该研究旨在为临床指南修订提供循证医学证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Microwave ablation (MWA) has achieved excellent long-term efficacy in treating unifocal papillary thyroid microcarcinoma (UPTMC). The therapeutic effect of this treatment on multifocal papillary thyroid microcarcinoma (MPTMC) is unknown. Therefore, we evaluated the long-term efficacy of MWA for low-risk MPTMC and to provide evidence-based medicine for the revision of clinical guidelines.
METHODS: This study included 66 MPTMC patients with a total of 158 lesions, all of whom received MWA. We collected and retrospectively analyzed the patients' follow-up data before MWA, at 1, 3, 6, and 12 months posttreatment and every 6 months thereafter until 5 years posttreatment. We evaluated the MWA complication rate, technical success rate (TSR), lesion volume reduction rate (VRR), and complete disappearance rate (CDR) during follow-up and in those patients with tumor progression and delayed surgery.
RESULTS: After 60 months of follow-up, all 158 lesions disappeared in 66 patients, and the volume was reduced from 43.82 mm3 to 0.00 mm3. The TSR and VRR were both 100%. The CDRs at 1 year, 2 years, and 3 years were 57.59%, 93.67%, and 100%, respectively. The complication rate was 3.03% (2/66), and the incidence of tumor progression was 3.03% (2/66), including one new intrathyroidal lesion and one cervical lymph node metastasis (LNM). These lesions were retreated with MWA, and the lesions disappeared during the follow-up period.
CONCLUSIONS: Ultrasound-guided MWA for low-risk MPTMC is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance (AS).
CLINICAL RELEVANCE STATEMENT: This study concludes that ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance.
KEY POINTS: • Ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective. • During 5 years of follow-up, multifocal papillary thyroid microcarcinoma patients treated with microwave ablation had a favorable prognosis. • To provide evidence-based medicine for the revision of clinical guidelines.
引用
- Dong P, Teng DK, Sui GQ, et al. Long-term efficacy of microwave ablation for multifocal papillary thyroid microcarcinoma: a 5-year follow-up study. Eur Radiol. 2023. PMID: 37581653. doi:10.1007/s00330-023-10117-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。